Business
iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740
About this update from Irhythm Holdings, Inc.
[{"type":"image","alt":"iRhythm","displaySize":"","headline":null,"caption":"iRhythm","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/f45ffedb3d05402e7e1d1906344ea62f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s9HO7ZqpsQD8YOjAXzOofg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f45ffedb3d05402e7e1d1906344ea62f","width":300,"height":43}},"lazy":false},{"type":"text","content":"SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference.","length":350,"tagName":"p"},{"type":"text","content":"Recent Operational Highlights and Financial Outlook","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter 2025","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"For full year 2026, expect revenue of approximately $870 million to $880 million, or approximately 17% to 18% year-over-year growth, and anticipate adjusted EBITDA margin of approximately 11.5% to 12.5%","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Recently-presented real-world evidence from over 1.4 million patients reinforces Zio long-term continuous monitoring (LTCM) clinical superiority, with APHRS 2025 data demonstrating consistent performance in Asian populations1, a Heart Rhythm publication confirming short-term monitoring misses actionable arrhythmias2, and AHA 2025 data validating successful at-home self-application and earlier detection in at-risk populations3-6","length":431,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":831,"olType":false},{"type":"text","content":""2025 has been a transformative year for iRhythm, with strong execution against our aspiration to drive best-in-class quality systems, record commercial volumes, over 25% year-over-year revenue growth, and achieving free cash flow ...